These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

81 related items for PubMed ID: 15876473

  • 1. Stronger anti-HIV-1 activity of C-peptide derived from HIV-1 89.6 gp41 C-terminal heptad repeated sequence.
    Seo JK, Kim HK, Lee TY, Hahm KS, Kim KL, Lee MK.
    Peptides; 2005 Nov; 26(11):2175-81. PubMed ID: 15876473
    [Abstract] [Full Text] [Related]

  • 2. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
    Gustchina E, Hummer G, Bewley CA, Clore GM.
    J Med Chem; 2005 Apr 21; 48(8):3036-44. PubMed ID: 15828842
    [Abstract] [Full Text] [Related]

  • 3. Design and evaluation of antiretroviral peptides corresponding to the C-terminal heptad repeat region (C-HR) of human immunodeficiency virus type 1 envelope glycoprotein gp41.
    Soonthornsata B, Tian YS, Utachee P, Sapsutthipas S, Isarangkura-na-Ayuthaya P, Auwanit W, Takagi T, Ikuta K, Sawanpanyalert P, Kawashita N, Kameoka M.
    Virology; 2010 Sep 15; 405(1):157-64. PubMed ID: 20580393
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Chemoenzymatic synthesis of HIV-1 gp41 glycopeptides: effects of glycosylation on the anti-HIV activity and alpha-helix bundle-forming ability of peptide C34.
    Wang LX, Song H, Liu S, Lu H, Jiang S, Ni J, Li H.
    Chembiochem; 2005 Jun 15; 6(6):1068-74. PubMed ID: 15883971
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
    Lu L, Tong P, Yu X, Pan C, Zou P, Chen YH, Jiang S.
    Biochim Biophys Acta; 2012 Dec 15; 1818(12):2950-7. PubMed ID: 22867851
    [Abstract] [Full Text] [Related]

  • 8. Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41.
    Jiang S, Debnath AK.
    Biochem Biophys Res Commun; 2000 Mar 24; 269(3):641-6. PubMed ID: 10720469
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
    Deng Y, Zheng Q, Ketas TJ, Moore JP, Lu M.
    Biochemistry; 2007 Apr 10; 46(14):4360-9. PubMed ID: 17371053
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A multi-functional peptide as an HIV-1 entry inhibitor based on self-concentration, recognition, and covalent attachment.
    Zhao L, Tong P, Chen YX, Hu ZW, Wang K, Zhang YN, Zhao DS, Cai LF, Liu KL, Zhao YF, Li YM.
    Org Biomol Chem; 2012 Aug 28; 10(32):6512-20. PubMed ID: 22760295
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.